Biocryst Pharmaceuticals Inc (BCRX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biocryst Pharmaceuticals Inc (BCRX)

BCRX 7.030

-1.8%

Nov 6 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: idos who wrote (156)	7/17/2007 4:18:02 PM
From: scaram(o)uche	Read Replies (1) of 269

The original PR re. Roche described a deal with $530 million biobucks. Bugg, of course, crowed for a year about how the deal was one of biotech's biggest. I wrote to I.R. at the company. We can stop waiting for them to issue the revised PR, there is no milestone for reaching phase II. I guess this is the Bugg subdivision of biobucks, impossibucks. Thank you for your interest in BioCryst. Let me begin by saying that we are very pleased to be working with Roche. We feel they are the ideal partner for BCX-4208. To address your question regarding milestones, there is not a milestone payment associated with the initiation of Phase IIa. Beyond that statement, we are not going to comment on future milestones until they are achieved. My contact information is below and I would welcome the opportunity to speak with you by phone if you are so inclined. Best regards, John Nugent. Jonathan M. Nugent Vice President Corporate Communications and Investor Relations BioCryst Pharmaceuticals, Inc. 2190 Parkway Lake Drive Birmingham, AL 35244 jnugent@biocryst.com 205-444-4633: office 205-566-3026: cell

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next